Schmid P, Jung KH, Wysocki PJ, et al. Datopotamab deruxtecan + durvalumab as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study. Ann Oncol. 2022;33(suppl 3):S199. doi:10.1016/j.an...
参考文献: [1]Adrian G., Preclinical investigation for the mechanisms of action of PARP inhibition in combination with trastuzumab deruxtecan T DXd in triple negative breast cancer TNBC. 2024 SABCS. P4-03-23. [2]Adrian G., Zhanfang G., Alice M., et al. Abstract P2-17-03: Preclinical ...
随着对HER2低表达分子生物学以及临床病理学等方面的深入研究,探索HER2低表达TNBC的精准治疗也成为乳腺癌领域的热点方向。 DESTINY-Breast04是首个聚焦HER2低表达晚期乳腺癌并取得阳性结果的III期研究。共纳入557例HER2低表达(IHC 1+、IHC 2+/ISH-)不可切除和/或转移性乳腺癌患者,其中HR-即TNBC患者为63例,占比11.3...
3. Shao ZM, et al. Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. 2024 SABCS. Abstract GS3-06. 4.待补充 5. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for earl...
IMDb Answers: Help fill gaps in our data Learn more about contributing Edit page List The Top 10 Most Popular Indian Web Series of 2024 See the list Photos The Year in Pictures See the gallery Recently viewed Please enable browser cookies to use this feature.Learn more....
To investigate the biological function of circPSMA1 in breast cancer cells, loss-of-function and gain-of-function assays were performed. The qRT-PCR results showed the circPSMA1 overexpression or knockdown efficiency of transfection with the circPSMA1 overexpression or RNAi vector (Fig. 2A, B);...
Phosphorylation proteomics is the basis for the study of abnormally activated kinase signaling pathways in breast cancer, which facilitates the discovery of new oncogenic agents and drives the discovery of potential targets for early diagnosis and therapy of breast cancer. In this study, we have explo...
Understanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the function of the S100A8/A9-RAGE sy
Triple-negative breast cancer (TNBC) cells’ secretome can induce a pro-inflammatory phenotype in human adipose-derived mesenchymal stem cells (hADMSC). This can be prevented by the green tea polyphenol epigallocatechin-3-gallate (EGCG). The impact of EGCG on the paracrine regulation that the ext...
[2] Shao Zhimin, Lei Fan, Ma Linxiaoxi, et al. FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer. 2023 ASCO Annual Meeting. J Clin Oncol 41, 2023 (suppl 16; abstr 3011). DOI: 10.1200/JCO.2023.41.16...